Grant: Banting Postdoctoral Fellowship Program
University of Calgary
$140,000.00
Engineering peptide-MHC/co-stimulator-based nanoparticle vaccines for the treatment of metastatic cancer
EF 2015-16
Résumé
Cancer is the leading cause of death in the world. Although the last decade has witnessed significant advances in the treatment of cancer, most cancers remain incurable, making this disorder an ongoing huge health care challenge for governments worldwide. Nanotechnology has the potential to radically change how we diagnose and treat cancer, such as by enhancing the efficacy and reducing the toxicity of cancer-fighting drugs. Immunotherapy (i.e. CAR-T technology as well as mAbs targeting immunoregulatory molecules on lymphocytes, such as PD-1 or CTLA-4) has most recently emerged as an important therapeutic approach for the treatment of cancer. The work described here represents an inter-disciplinary effort to bridge these two disciplines and develop a safe and effective nanoparticle-based immunotherapeutic platform for in vivo manipulation of immune responses against metastatic cancer.
Programme
Banting Postdoctoral Fellowship Program
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
335866
Name
Shao Kun
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Banting Postdoctoral Fellowships Program
Projecttitle
Engineering peptide-MHC/co-stimulator-based nanoparticle vaccines for the treatment of metastatic cancer
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Banting Postdoctoral Fellowship Program
Keyworddelim
Biomaterials; Bionanomedicines; Cancer Immunotherapy; Co-Stimulatory Molecules; Metastatic Cancer; Nanovaccines; Peptide-Major Histocompatibility Complexes
Abstract
Cancer is the leading cause of death in the world. Although the last decade has witnessed significant advances in the treatment of cancer, most cancers remain incurable, making this disorder an ongoing huge health care challenge for governments worldwide. Nanotechnology has the potential to radically change how we diagnose and treat cancer, such as by enhancing the efficacy and reducing the toxicity of cancer-fighting drugs. Immunotherapy (i.e. CAR-T technology as well as mAbs targeting immunoregulatory molecules on lymphocytes, such as PD-1 or CTLA-4) has most recently emerged as an important therapeutic approach for the treatment of cancer. The work described here represents an inter-disciplinary effort to bridge these two disciplines and develop a safe and effective nanoparticle-based immunotherapeutic platform for in vivo manipulation of immune responses against metastatic cancer.
Competitiondate
201509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Shao, Kun
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~